By Fineline Cube 
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase III KEYNOTE-B96 trial (also known as ENGOT-ov65). The trial met its primary endpoint of progression-free survival (PFS) in patients with platinum-resistant recurrent ovarian cancer, including those with PD-L1-expressing tumors and all comers. Additionally, the study achieved a secondary endpoint of overall survival (OS) in the PD-L1-positive subgroup.
Trial Details and Results
The randomized, double-blind Phase III trial evaluated the efficacy and safety of Keytruda (pembrolizumab), MSD’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) ± bevacizumab. Results demonstrated that the Keytruda-based regimen provided statistically significant and clinically meaningful improvements in PFS, regardless of PD-L1 status. Furthermore, in PD-L1-positive patients with a Combined Positive Score (CPS) ≥1, the regimen showed improvements in OS compared to placebo plus chemotherapy ± bevacizumab.-Fineline Info & Tech